Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 17/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857140 | 0.90 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL3119489 | 0.84 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL3116778 | 0.84 | HSP90AA1 (0.73) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL2604977 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1966947 | 0.82 | ERBB2 (0.82) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL10149974 | 0.78 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1963368 | 0.78 | ERBB2 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL4854328 | 0.77 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2 | |
| SCHEMBL23819778 | 0.77 | HSP90AA1 (0.81) | HSP90AA1HSP90AB1ERBB2HSP90B1 | |
| SCHEMBL1864541 | 0.75 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1ERBB2HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-7241890-B2 | Purine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125446-A1 | Purine analogs having HSP90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885ERBB2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.